JW (Cayman) Therapeutics Co. Ltd
JWCTF
Other OTC0.20
USD
- -
- -
ISIN
KYG5210T1040
CUSIP
G5210T104
Return %
Stock
S&P500
1Y
-19.11
19.01
3Y
-37.78
65.48
5Y
-92.90
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Tian Feng
- Full Time Employees
- 314
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building B Shanghai SH People's Republic of China
- IPO Date
- Jul 15, 2021
- Website
- jwtherapeutics.com
- Similar Companies
- Business
- JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company specializing in the development, manufacturing, and commercialization of cell-based immunotherapies targeting hematological cancers, solid tumors, and autoimmune diseases. The company’s core products include Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy approved for the treatment of relapsed or refractory large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma in China, as well as ongoing development programs for systemic lupus erythematosus and novel CAR-T candidates targeting antigens such as MAGE-A4 and multiple myeloma. JW Therapeutics operates an integrated cell therapy development platform and commercial manufacturing infrastructure primarily in China. Founded in 2015 and headquartered in Shanghai, the company is listed on the Hong Kong Stock Exchange. Recent significant developments include the expansion of its strategic collaboration with Regeneron Pharmaceuticals to advance TCR-T cell therapy development and oncology product pipelines in Greater China. In 2025, JW Therapeutics secured approvals and breakthrough therapy designations from Chinese regulatory authorities for Carteyva in additional lymphoma indications and is progressing clinical trials to explore its use in frontline and second-line treatments. The company also amended the collaboration framework with Regeneron, which includes Regeneron funding development activities and milestone payments while granting non-exclusive global licenses for certain drug product processes excluding Greater China. JW Therapeutics has also engaged in licensing agreements with Juno Therapeutics to leverage manufacturing processes and extend its product manufacturing capabilities. These moves reinforce JW Therapeutics’ position as a leader in cell immunotherapy innovation and commercial execution in the Asia-Pacific region.